Brief: Reviva Pharmaceuticals Holdings Reports Full Year 2022 Financial Results

Reviva Pharmaceuticals Holdings

30/03/2023 12:36

March 30 (Reuters) - Reviva Pharmaceuticals Holdings,
Inc.  RVPH.O :
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. REPORTS FULL YEAR
2022 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - FY LOSS PER SHARE
$1.25
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - AS OF DECEMBER 31,
2022,
CASH AND CASH EQUIVALENTS TOTALED ABOUT $18.5 MILLION
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - CASH AS OF
DECEMBER 31,
2022 WILL BE SUFFICIENT TO FUND CURRENT OPERATING PLANS THROUGH
Q3 OF 2023
    * REVIVA PHARMACEUTICALS HOLDINGS - TOPLINE DATA FOR PHASE 3
TRIAL
EVALUATING BRILAROXAZINE FOR TREATMENT OF SCHIZOPHRENIA REMAINS
ON TRACK FOR MID-2023

Source text for Eikon:  ID:nGNX5Hjcgw 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))